Glide Technologies Announces Successful Proof-of-Concept with Novel Exenatide Solid Dose Formulation

Glide Technologies has announced that they have successfully completed a pre-clinical proof-of-concept study with its novel solid dose formulation of exenatide, a GLP-1 agonist for the treatment of Type 2 diabetes.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news